– A maxirisarcimento from 1,200 million euro as required by the Ministry of Health to pharmaceutical companies Novartis, Roche and Hoffmann for the story of the marketing of the drugs Lucentis and Avastin. The sponsor of the competition had in fact qualified as “a horizontal restrictive” free-market behavior of companies to sell Lucentis, Avastin more expensive than equivalent. Asked 14 million to Pfizer.
deliberation about the scandal of the Lucentis-Avastin was prepared in February this year, and it is defined precisely the behavior of the company Hoffman-La Roche Ltd., Roche Spa, Novartis AG and Novartis Farma Spa as “a horizontal agreement restricting competition aimed at the commercialization of the drug Lucentis, very more expensive drug Avastin, equivalent to it. ” Following this document was required to pharmaceutical companies involved “compensation for all damage to property”, estimated at 45 million in 2012, 540 in 2013 and 615 in 2014, and those “non-property wrongfully caused to the NHS.”
case Xalatan – For Pfizer, the decision of the Competition January 11, 2012, upheld on judicial review by the State Council on February 12, said the Ministry of Health in a statement, “has defined the conduct engaged in by Pfizer ‘characterized by a clear and insisted anti-competitive intent, seeking to delay the marketing of generic drugs, even with considerable damage to the national health service.’” As a result the ministry has requested “damages, both the balance sheet (EUR 14 million) and non-pecuniary, suffered by the National Health Service in respect of the Italian company Pfizer Ltd., Pfizer Inc. and Pfizer Health AB, due to the behavior of abuse of dominant position held by them in connection with the marketing of the drug Xalatan. “
Roche replied:” Figures unreal “ – La Roche expresses” his whole surprise “for the request compensation for damages by the Ministry of Health and precise in a statement that “the figures still seem unreal.” The drugmaker added that “the measure upon which the request is the subject of an appeal before the TAR of Lazio and that there is a judgment, not of first degree, awarded to companies that have the responsibility for the alleged damage, nor does it quantify the damage “.
Novartis’ request compensation unfounded” – For Novartis “any claim is groundless as well as the figures given in the statement of the Ministry, which there is no correspondence with the reality of the facts. ” So says the claim that the pharmaceutical company in a statement said that “will make use of their rights of defense in all relevant fora.” “The spending generated by Lucentis to the NHS in January-September 2013 – Novartis precise – was equal to 38.6 million euro, in line with the data recorded in 2012.”
If the blurred vision contributes the risk of falls in the elderly, change glasses and use new ones, with a change in the prescription, it could also increase this kind of danger, rather than decrease it. To support it, a new study published in ‘Optometry and Vision Science’, the official journal of the American Academy of Optometry, by David B. Elliot and his group at the University of Bradford, UK. Falls are the leading cause of accidental death and non-fatal injury in older adults in the United States. At least one-third of healthy adults age ‘of 65 years fall at least once a year. For those of eta ‘more than 90 years, then, the risk increases to approximately 60 percent. The reduced vision and ‘an important risk factor, which suggests that interventions to correct vision, in particular spectacles and cataract surgery, reduce the risk of experiencing falls. However, the glasses with new shades can make objects appear more ‘neighbors or more’ away than they really are, thus influencing ‘the reflections that connect the vestibular system of balance with eye movements, and thus inducing’ falls. 
L ‘Annual Meeting of the World Health’ Organization (WHO) meeting in Geneva, approved the “Plan first ever worldwide” to end the preventable deaths of infants and cases of stillbirths by 2035.’s plan – says the World Health Organization ‘- calls on countries to pursue the objective to record less than 10 infant deaths per 1,000 live births and stillbirths less than 10 per 1000 live births by 2035. Every year nearly 3 million children die in the first month of life and the stillbirth-rate (death in the last 3 months of pregnancy or during childbirth) are 2.6 million. According to the WHO, most of these deaths could be prevented by effective interventions also from the point of view of the costs (cost-effective). The objectives of the Plan will require all countries to invest in high-quality care ‘for interventions and coaching before, during and after birth for every pregnant woman and her baby boy. During the annual meeting (May 19 to 24), the 67 / World Health Assembly ‘has approved more’ than 20 resolutions on public health issues of global importance, the fight against drug-resistance access to basic medicines and palliative care to the challenge of violence that affects women and girls in particular. To the Director-General of WHO, Dr Margaret Chan, and ‘treaty’ assembly intense, with a record number of agenda items, documents and resolutions and nearly 3,500 registered delegates. ” This, said Chan, “reflects the growing complexity ‘of a large number of health issues and the keen interest of governments to deal with them.” The World Health Assembly ‘and’ the supreme decision-making body of WHO. E ‘, among other things, responsible for determining the policies of the Organization, the Director-General to appoint, supervise the financial policies and approve the budget for the proposed program. 
